[{"orgOrder":0,"company":"Xcellon Biologics","sponsor":"Invenra","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Xcellon Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xcellon Biologics \/ Xcellon Biologics","highestDevelopmentStatusID":"3","companyTruncated":"Xcellon Biologics \/ Xcellon Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Xcellon Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : The collaboration aims to advance the development of an undisclosed antibody-drug conjugate in an undisclosed target area.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          October 22, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Recipient : Invenra

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank